查詢結果分析
相關文獻
- A Survey on the Treatment Strategy of Patent Ductus Arteriosus in Very Low-Birth-Weight Infants
- Symptomatic Patent Ductus Arteriosus in Very Low Birth Weight Infants
- Comparison of the Outcome of Extremely-Low-Birth-Weight Infants between Two Periods
- 極低體重兒使用中鍵/長鍵三酸甘油脂靜脈營養的效果評估
- Concurrent Transcatheter Closure of Patent Ductus Arteriosus and Coronary Angioplasty in An Old Man
- Early Outcome of Extremely Low Birth Weight Infants in Taiwan
- Prognostic Value of Color Doppler Echocardiographic Findings in Premature Newborns with Patent Ductus Arteriosus
- Glutamine Supplementation for Low-Birth-Weight and Very Low-Birth-Weight Infants
- Rigid Bronchoscopy and Jet Ventilation in an Extremely Low Birthweight Infant
- 間隔性方法對極低體重兒鈣質代謝的分析
頁籤選單縮合
題名 | A Survey on the Treatment Strategy of Patent Ductus Arteriosus in Very Low-Birth-Weight Infants=極低體重兒存開性動脈導管治療方法之調查 |
---|---|
作者 | 蘇百弘; 胡博翔; 黃鴻偉; 劉凌玉; 楊鵬弘; 葉秀珍; Su, Bai-horng; Hu, Paul-shiang; Huang, Hung-wei; Liu, Lin-yu; Yang, Peng-hong; Billiet, Marguerite; |
期刊 | 中華民國小兒科醫學會雜誌 |
出版日期 | 19980100、19980200 |
卷期 | 39:1 民87.01-02 |
頁次 | 頁33-37+69 |
分類號 | 417.509 |
語文 | eng |
關鍵詞 | 極低體重兒; 存開性動脈導管; Very low-birth-weight infants; Patent ductus arteriosus; Indomethacin; |
中文摘要 | 本研究目的為回溯性檢討極低體重兒存開性動脈導管(PDA)之治療。研究對象 為自1996年1月1日至1996年12月31日止在四家醫院的新生兒加護病房住院的出生體重 小於1500公克患有症候性PDA之早產兒。共收集了67名個案為研究之材料。結果顯示56 個嬰兒(83.6%)有呼吸窘迫症候群(RDS),其中有53名(79%)接受Survanta補充治療。 平均懷孕週數27.9±2.4週,平均出生體重1078±293公克。用來做為使用Indomethacin治 療PDA的基準為:有一家醫院以CVD≧3為唯一的基準,另外三家醫院主要是以彩色Doppler 心臟超音波檢查做為治療的基準,有時會以LA╱AO≧1.3為治療的基準。其中有2家醫院 有時也會使用Pulsed Doppler心臟超音波檢查做為治療的基準。有7名嬰兒(10.5%)合併 有Indomethacin的使用禁忌,其中3名接受外科結紮術,4名接受保守性內科療法而使PDA 關閉。另外60名嬰兒,除了3名接受口服Indomethacin治療以外,都是接受靜注Indomethacin 治療。初回治療日齡平均為3.8±1.5天,其中10名(16.7%)24小時內,25名(41.7%) 在24∼48小時內,25名(41.7%)超過生後48小時。Indomethacin的劑量為每回0.2mg/kg, 如果沒有投予禁忌,每隔12∼24小時投予以3回為一個course。平均接受Indomethacin 劑 數為2.8±1.5,PDA關閉率為85%(51/60)。有25名嬰兒(41.7%)只接受1劑或2劑,其 PDA關閉率為84%(21/25)。有32∼52%的嬰兒發生Indomethacin治療後的併發症,大都 發生在生後48小時內接受首劑Indomethacin的嬰兒。合併有RDS的早產兒其首劑治療日齡 比沒有合併RDS的早產兒為早(3.3±2.5天 VS. 7.6±5.6天;P<0.05)而且較高的PDA 關閉率(89%VS. 57%;P<0.05)。結論是在極低體重兒使用Indomethacin可以使症候性PDA 關閉。即使只接受1劑或2劑的嬰兒也有PDA關閉的機會。為了減少在極低體重兒使用 Indomethacin發生併發症的機率,對現行使用Indomethacin的方法有再加評估的必要。 |
英文摘要 | This study is a retrospective analysis of the clinical data of 67 very low birth weight infants ( VLBWI ) with symptomatic patent ductus arteriosus ( PDA ); all were admitted to four neonatal intensive care units ( NICU ) from January 1, 1996 through December 31, 1996. The mean gestational age was 27.9 ± 2.4 weeks, the mean birth weight was 1078 ± 293 g. Fifty-six infants ( 83.6% ) had RDS, and 53 infants ( 79% ) received artificial surfactant. The NICU at a regional hospital used CVD score ≧3 as the sole criteria and the remaining three NICUs used color Doppler echocardiogram to confirm a symptomatic PDA and to treat it; sometimes LA/AO ≧1.3 was used as the criteria for indomethacin treatment. Two of these three hospitals sometimes used the pulsed Doppler echocardiogram as well as color Doppler examination as the treatment criteria. Seven infants ( 10.5% ) had contraindication for indomethacin treatment; four of them closed after conservative treatment, and another three were subjected to surgical ligation. Of the remaining 60 infants, 3 were treated with oral indomethacin and 57 were treated with intravenous indomethacin. The mean age when initial treatment given was 3.8 ± 1.5 days ( range, 8 hours~20days ). Among them 10 ( 16.7% ) were within 24 hours after birth, 25 ( 41.7% ) were between 24 and 48 hours, and 25 ( 41.7% ) were beyond 48 hours. The dosage of indomethacin was 0.2 mg/kg per dose intravenously every 12 to 24 hours for three doses as a full course, if not contraindicated. The mean dose of indomethacin was 2.8 ± 1.5; 10 infants ( 16.7% ) received 1 dose, 15 ( 25% ) received 2 doses, 27 ( 45% ) received 3 doses, 3 ( 5% ) received 4 doses and 5 ( 8.3% ) received 6 doses. Among them, 51 infants ( 85% ) PDA closed ( including 2 treated with oral indomethacin ), 9 ( 15% ) failed to close and 6 of them received surgical ligation ( including 1 treated with oral indomethacin ). The complications associated with indomethacin treatment were hypoglycemia ( 52% ), decreased urine output ( 42% ) and gastrointestinal hemorrhage ( 32% ). The infants with RDS had an earlier mean age of initial treatment than non-RDS infants ( 3.3 ± 2.5 vs. 7.6 ± 5.6 days; p<0.05 ), and also had a higher closure rate ( 89% vs. 57%; p<0.05 ). There was a closure rate of 85% in this multicenter retrospective analysis. Even though the infants received only one or two doses, they still had a good chance of ductal closure ( 21/25, 84% ). To minimize the complications associated with indomethacin treatment in VLBWI, the protocol of indomethacin treatment should be re-evaluated. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。